Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Celldex Therapeutics, Inc. Snapshot 7
Celldex Therapeutics, Inc. Overview 7
Key Information 7
Key Facts 7
Celldex Therapeutics, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Celldex Therapeutics, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Celldex Therapeutics, Inc. – Pipeline Products Glance 14
Celldex Therapeutics, Inc. – Late Stage Pipeline 14
Phase III Products/Combination Treatment Modalities 14
Celldex Therapeutics, Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Celldex Therapeutics, Inc. – Early Stage Pipeline Products 17
Pre-Clinical Products/Combination Treatment Modalities 17
Celldex Therapeutics, Inc. – Drug Profiles 18
CDX-011 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CDX-014 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CDX-1127 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDX-1135 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CDX-1401 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CDX-1401 + Resiquimod 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CDX-301 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DCVax-001 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Rindopepimut 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Celldex Therapeutics, Inc. – Pipeline Analysis 27
Celldex Therapeutics, Inc. – Pipeline Products by Therapeutic Class 27
Celldex Therapeutics, Inc. – Pipeline Products By Target 29
Celldex Therapeutics, Inc. – Pipeline Products by Route of Administration 30
Celldex Therapeutics, Inc. – Pipeline Products By Mechanism of Action 31
Celldex Therapeutics, Inc. – Recent Pipeline Updates 32
Celldex Therapeutics, Inc. - Dormant Projects 36
Celldex Therapeutics, Inc. – Company Statement 37
Celldex Therapeutics, Inc. – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Celldex Therapeutics, Inc. - Key Manufacturing Facilities 42
Celldex Therapeutics, Inc., Recent Developments 43
Celldex Therapeutics, Inc.- Press Release 43
Jan 17, 2012: Celldex Therapeutics Initiates Phase I Clinical Trial Of CDX-301 For Hematopoietic Stem Cell Transplantation 43
Jan 04, 2012: Celldex Initiates Phase II Study Of Rindopepimut In Combination With Avastin In Patients With Recurrent Glioblastoma 43
Dec 13, 2009: Celldex Announces Positive Results From Phase II Study Of CDX-011 In Advanced Breast Cancer 44
Dec 13, 2009: Celldex Therapeutics Presents Positive Phase 2 Study Results Of CDX-011 For The Treatment Of Advanced Breast Cancer 45
Dec 07, 2009: Celldex To Present CDX-011 Clinical Data At 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium 46
Oct 29, 2009: Celldex Therapeutics Presents Positive Clinical Data From Phase I Study Of CDX-1307 46
Sep 14, 2009: Celldex Therapeutics Announces Dosing Of First Patient In Phase I/II Clinical Trial Of CDX-1401 47
Jun 01, 2009: Celldex Therapeutics Announces Clinical Data Of CDX-1307 At 45th Annual ASCO Meeting 48
May 30, 2009: Pfizer And Celldex Therapeutics Present Update On CDX-110 (PF-04948568) Phase II Brain Cancer Studies At 45th Annual ASCO Meeting 48
Financial Deals Landscape 50
Celldex Therapeutics, Inc., Deals Summary 50
Celldex Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 52
Asset Transactions 52
Celldex Therapeutics Acquires Rights To Immune Stimulatory Molecules From Amgen 52
Partnerships 54
AVANT Immunotherapeutics Enters Into Research Agreement With Select Vaccines 54
Merger 55
AVANT Immunotherapeutics Merges With Celldex Therapeutics 55
Licensing Agreements 57
Celldex Therapeutics Enters Into A Licensing Agreement With 3M Company 57
Celldex Therapeutics Enters Into An Agreement With Vaccine Technologies 58
Celldex Enters Into An Agreement With University of Southampton 59
Celldex Therapeutics Enters Into License And Development Agreement With Pfizer 60
Celldex Therapeutics Enters Into Licensing Agreement With Ludwig Institute 62
Celldex Therapeutics Enters Into Licensing Agreement With Duke University 64
Celldex Therapeutics Enters Into Licensing Agreement With The Rockefeller University 66
Avant Immunotherapeutics Enters Into Licensing Agreement With Adprotech 67
Equity Offering 68
Celldex Therapeutics Announces Underwriters' Exercise Of Over-Allotment Option For $46 Million 68
Celldex Therapeutics Completes An Underwritten Public Offering Of $32 Million 71
AVANT Immunotherapeutics Completes Private Placement Of $24.65 Million 74
Acquisition 76
Celldex Therapeutics Completes Acquisition Of CuraGen 76
Celldex Therapeutics Acquires Lorantis 78
Celldex Therapeutics Acquires Alteris Therapeutics 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
List of Tables
Celldex Therapeutics, Inc., Key Information 7
Celldex Therapeutics, Inc., Key Facts 7
Celldex Therapeutics, Inc. – Pipeline by Indication, 2012 9
Celldex Therapeutics, Inc. – Pipeline by Stage of Development, 2012 11
Celldex Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 12
Celldex Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
Celldex Therapeutics, Inc. – Phase III, 2012 14
Celldex Therapeutics, Inc. – Phase II, 2012 15
Celldex Therapeutics, Inc. – Phase I, 2012 16
Celldex Therapeutics, Inc. – Pre-Clinical, 2012 17
Celldex Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012 28
Celldex Therapeutics, Inc. - Pipeline By Target, 2012 29
Celldex Therapeutics, Inc. – Pipeline By Route of Administration, 2012 30
Celldex Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012 31
Celldex Therapeutics, Inc. – Recent Pipeline Updates, 2012 32
Celldex Therapeutics, Inc. - Dormant Developmental Projects,2012 36
Celldex Therapeutics, Inc., Other Locations 41
Celldex Therapeutics, Inc., Subsidiaries 41
Celldex Therapeutics, Inc., Key Manufacturing Facilities 42
Celldex Therapeutics, Inc., Deals Summary 50
Celldex Therapeutics Acquires Rights To Immune Stimulatory Molecules From Amgen 52
AVANT Immunotherapeutics Enters Into Research Agreement With Select Vaccines 54
AVANT Immunotherapeutics Merges With Celldex Therapeutics 55
Celldex Therapeutics Enters Into A Licensing Agreement With 3M Company 57
Celldex Therapeutics Enters Into An Agreement With Vaccine Technologies 58
Celldex Enters Into An Agreement With University of Southampton 59
Celldex Therapeutics Enters Into License And Development Agreement With Pfizer 60
Celldex Therapeutics Enters Into Licensing Agreement With Ludwig Institute 62
Celldex Therapeutics Enters Into Licensing Agreement With Duke University 64
Celldex Therapeutics Enters Into Licensing Agreement With The Rockefeller University 66
Avant Immunotherapeutics Enters Into Licensing Agreement With Adprotech 67
Celldex Therapeutics Announces Underwriters' Exercise Of Over-Allotment Option For $46 Million 68
Celldex Therapeutics Completes An Underwritten Public Offering Of $32 Million 71
AVANT Immunotherapeutics Completes Private Placement Of $24.65 Million 74
Celldex Therapeutics Completes Acquisition Of CuraGen 76
Celldex Therapeutics Acquires Lorantis 78
Celldex Therapeutics Acquires Alteris Therapeutics 79

List of Figures
List of Figures
Celldex Therapeutics, Inc. – Pipeline by Indication, 2012 9
Celldex Therapeutics, Inc. – Pipeline by Stage of Development, 2012 11
Celldex Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 12
Celldex Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
Celldex Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012 27
Celldex Therapeutics, Inc. - Pipeline By Target, 2012 29
Celldex Therapeutics, Inc. – Pipeline By Route of Administration, 2012 30
Celldex Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2012 31